Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Skye Bioscience, Inc. is a biotechnology company developing GPCR-modulating molecules for obesity and metabolic disorders. Its lead candidate, nimacimab, is a monoclonal antibody targeting peripheral CB1 receptors to promote weight loss, energy expenditure, and metabolic health. The company focuses on clinical-stage therapeutics, leveraging proprietary platform technologies, with a competitive edge in safety, specificity, and innovative mechanisms to address unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.